 The drug being tested is TAK-659.This study will look at the determination of the MTDRP2D and efficacy measured by ORR in participants who take TAK-659 in combination with nivolumab. The study will include a dose escalation phase Part 1, a potential nivolumab fixed dose cohort, and a dose expansion phase Part 2. 